Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice

[1]  A. Ore,et al.  Oxidative Stress and Antioxidant Biomarkers in Clinical and Experimental Models of Non-Alcoholic Fatty Liver Disease , 2018, Medicina.

[2]  L. Ramalho,et al.  Aliskiren effect on non-alcoholic steatohepatitis in metabolic syndrome , 2017, Diabetology & Metabolic Syndrome.

[3]  D. Cassiman,et al.  Development of a Representative Mouse Model with Nonalcoholic Steatohepatitis , 2016, Current protocols in mouse biology.

[4]  D. Jump,et al.  Is Western Diet-Induced Nonalcoholic Steatohepatitis in Ldlr-/- Mice Reversible? , 2016, PloS one.

[5]  S. Friedman,et al.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis. , 2015, Gastroenterology.

[6]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[7]  J. Auwerx,et al.  Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis , 2014, Gut.

[8]  Aijaz Ahmed,et al.  Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. , 2014, Hepatology.

[9]  F. Nevens,et al.  P245 ROUX-EN-Y GASTRIC BYPASS ATTENUATES HEPATIC MITOCHONDRIAL DYSFUNCTION IN MICE WITH NONALCOHOLIC STEATOHEPATITIS , 2014 .

[10]  V. Arroyo,et al.  Resolvin D1 primes the resolution process initiated by calorie restriction in obesity‐induced steatohepatitis , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  平田 匠.  Effect of telmisartan or losartan for treatment of nonalcoholic fatty liver disease : fatty liver protection trial by telmisartan or losartan study (FANTASY) , 2014 .

[12]  M. Muiesan,et al.  Nutraceuticals and dyslipidaemia: Beyond the common therapeutics , 2014 .

[13]  J. Rieusset,et al.  Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  V. Ratziu,et al.  Pharmacological agents for NASH , 2013, Nature Reviews Gastroenterology &Hepatology.

[15]  R. Rector,et al.  The role of angiotensin II in nonalcoholic steatohepatitis , 2013, Molecular and Cellular Endocrinology.

[16]  Luca Valenti,et al.  Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment , 2013, Current pharmaceutical design.

[17]  R. Dalle Grave,et al.  The role of lifestyle change in the prevention and treatment of NAFLD. , 2013, Current pharmaceutical design.

[18]  M. Yeh,et al.  Dietary modification dampens liver inflammation and fibrosis in obesity‐related fatty liver disease , 2013, Obesity.

[19]  F. Nevens,et al.  Treatment of non-alcoholic fatty liver disease: can we already face the epidemic? , 2013, Acta gastro-enterologica Belgica.

[20]  R. Morishita,et al.  Potential effect of angiotensin II receptor blockade in adipose tissue and bone. , 2013, Current pharmaceutical design.

[21]  Simona Calugi,et al.  Stage of change and motivation to healthier lifestyle in non-alcoholic fatty liver disease. , 2013, Journal of hepatology.

[22]  L. Afman,et al.  Phenotyping the effect of diet on non-alcoholic fatty liver disease. , 2012, Journal of hepatology.

[23]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[24]  Christian Thoma,et al.  Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. , 2012, Journal of hepatology.

[25]  D. Schuppan,et al.  Anti-fibrotic therapy: lost in translation? , 2012, Journal of hepatology.

[26]  J. Heimbach,et al.  Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.

[27]  N. Lundbom,et al.  Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans. , 2011, The American journal of clinical nutrition.

[28]  N. Chalasani,et al.  Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.

[29]  R. Morishita,et al.  Obesity and gastrointestinal hormones-dual effect of angiotensin II receptor blockade and a partial agonist of PPAR-γ. , 2011, Current vascular pharmacology.

[30]  Jan Gunst,et al.  Insufficient activation of autophagy allows cellular damage to accumulate in critically ill patients. , 2011, The Journal of clinical endocrinology and metabolism.

[31]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[32]  H. Yki-Järvinen.  Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data , 2010, Current opinion in clinical nutrition and metabolic care.

[33]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[34]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[35]  H. Yoshiji,et al.  Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat , 2009, BMC Research Notes.

[36]  G. Bjørkøy,et al.  Monitoring autophagic degradation of p62/SQSTM1. , 2009, Methods in enzymology.

[37]  E. Georgescu.  Angiotensin receptor blockers in the treatment of NASH/NAFLD: Could they be a first-class option? , 2008, Advances in therapy.

[38]  D. Cassiman,et al.  NASH may be trash , 2008, Gut.

[39]  J. Miquel,et al.  Effect of losartan on early liver fibrosis development in a rat model of nonalcoholic steatohepatitis , 2007, Journal of gastroenterology and hepatology.

[40]  E. Georgescu,et al.  Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. , 2007, Journal of gastrointestinal and liver diseases : JGLD.

[41]  G. Bergström,et al.  Blood pressure is the major driving force for plaque formation in aortic-constricted ApoE−/− mice , 2006, Journal of hypertension.

[42]  G. Bedogni,et al.  Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study , 2005, Hepatology.

[43]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[44]  Y. Tokusashi,et al.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis , 2004, Hepatology.

[45]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[46]  V. Paradis,et al.  Sampling variability of liver fibrosis in chronic hepatitis C , 2003, Hepatology.

[47]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.